MGMT Fusion Polypeptide Enhances Recombinant Protein Yield

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current protein production systems, such as bacterial and eukaryotic cell cultures, face challenges with reproducibility, quality, and stability of recombinant protein expression, particularly in achieving high yields and correct folding, which limits industrial and pharmaceutical applications.

Innovation Solution

The use of a nucleotide vector encoding a fusion polypeptide comprising a viral protein linked with the 6-methylguanine-DNA-methyltransferase (MGMT) enzyme, which enhances protein production by co-expression in host cells, improving secretion and stability of recombinant proteins, achieving yields up to 200 mg/L in the supernatant.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If prokaryotic cell culture systems are used for protein production, then ease of maintenance and low operating cost are achieved, but correct folding and post-translational modification of eukaryotic proteins cannot be performed

Engineering Contradiction:
Improveease of maintenanceVSAvoidcorrect folding
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent uses insect cells as an intermediary system between prokaryotic simplicity and eukaryotic complexity. Insect cells can be cultured in relatively simple conditions like prokaryotes but possess eukaryotic machinery for correct protein folding and post-translational modifications, thus mediating the contradiction between ease of manufacture and manufacturing precision

Inventive Principle:
Principle #24Intermediary (Mediator)

2Manufacturing precision

If mammalian cell systems are used for protein production, then correct folding and post-translational modification are achieved, but expensive culture facilities and risk of infection are required

Engineering Contradiction:
Improvecorrect foldingVSAvoidspecialised culture facilities
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent employs insect cell lines that can be rapidly cultured and discarded, replacing the need for expensive, specialized mammalian cell culture facilities. The insect cells serve as disposable bioreactors that achieve correct folding without requiring the complex infrastructure needed for mammalian cells

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Productivity

If baculovirus expression vectors are used in insect cells, then protein production is achieved, but reproducibility and stability of expression levels are problematic

Engineering Contradiction:
Improveprotein productionVSAvoidreproducibility
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent extracts the polyhedrin gene from the baculovirus vector, eliminating the viral replication machinery that causes instability and reproducibility issues. The system uses insect cells transfected with the polyhedrin promoter-driven expression cassette without requiring actual virus infection, thereby maintaining high productivity while improving reliability

Inventive Principle:
Principle #2Taking out (Extraction)

4Productivity

If S2 cells are used for continuous expression, then higher expression levels are achieved, but specialised culture facilities and infection risk remain

Engineering Contradiction:
Improveexpression levelsVSAvoidspecialised culture facilities
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent makes the S2 cell system universal by using insect cells that can be cultured in simple defined media without specialized facilities. The system combines the high expression capability of S2 cells with the simplicity of prokaryotic culture conditions, eliminating the need for specialized infrastructure while maintaining continuous expression capability

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentEP3202897B1Diagnostic use of a fusion polypeptide comprising a viral protein and a MGMT enzyme
Publication Date: 2020.04.15 INST PASTEUR
  • EP3202897B1 patent drawingFigure 1A
  • EP3202897B1 patent drawingFigure 1B
  • EP3202897B1 patent drawingFigure 2A

AI summary

The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.